CAPLIPOINT - Swing Trade Analysis with AI Signals

Last Updated Time : 19 Sept 25, 2:15 pm

Swing Trade Rating: 4.0

📊 Technical & Fundamental Snapshot

✅ Strengths

MACD at 51.6 and RSI at 66.0 — strong bullish momentum, approaching breakout zone.

Price above DMA50 (₹2,144) and DMA200 (₹2,035) — confirms a well-supported uptrend.

ROCE (28.6%) and ROE (22.0%) — excellent operational and equity efficiency.

EPS ₹46.4 and Qtr Profit Var +18.4% — consistent earnings growth.

Debt-to-equity 0.00 — zero leverage, financially robust.

FII (+0.43%) and DII (+0.22%) holding increased — institutional confidence.

⚠️ Watchouts

P/E of 49.8 vs industry 33.4 — premium valuation.

PEG ratio 2.27 — expensive relative to growth.

Volume below average — short-term participation cooling.

Dividend yield 0.26% — minimal income cushion.

52w Index at 70.1% — trading near upper range, limited upside without breakout.

🧭 Trend Context (September 2025)

Caplin Point Laboratories is consolidating near its 25-day moving average and showing signs of strength. Analysts note that the stock has delivered a 3.15% gain in the last 5 days and is trading in the ₹2,169–₹2,224 range

1

. With strong fundamentals and a clean balance sheet, the stock is positioned for a potential breakout if volume returns.

🎯 Optimal Entry Price

Ideal entry: ₹2,200–₹2,230, near short-term support and breakout zone.

Confirm entry only if RSI stays below 70 and MACD remains positive with volume >1.5L.

🚪 Exit Strategy (If Already Holding)

Target zone: ₹2,480–₹2,600 (near resistance and 52-week high).

Stop-loss: ₹2,140 (below DMA50 and recent swing low).

Exit trigger: RSI > 75 or MACD divergence near ₹2,600.

This setup offers a technically strong swing with solid fundamentals and institutional backing. If you're basket-optimizing across mid-cap pharma or zero-debt plays, I can scan for peers with similar ROCE and breakout setups. Just say the word.

1

www.livemint.com

Edit in a page